News
CSBR
4.940
-1.59%
-0.080
Weekly Report: what happened at CSBR last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at CSBR last week (0311-0315)?
Weekly Report · 03/18 11:50
Champions Oncology Cut to Hold From Buy by Craig-Hallum
Dow Jones · 03/13 12:31
Craig-Hallum Downgrades Champions Oncology to Hold
Benzinga · 03/13 12:21
Champions Oncology Non-GAAP EPS of -$0.16, revenue of $12M
Seeking Alpha · 03/12 21:18
Champions Oncology: Q3 Earnings Insights
Champions Oncology reports its Q3 earnings on March 12, 2024. Champions oncology missed estimated earnings by $0.16. The company's revenue was down $754 thousand from the same period last year. Champions Oncologist is expected to report its earnings on Tuesday, March 12.
Benzinga · 03/12 20:45
Champions Oncology Q3 Adj $(0.16) Misses $(0.15) Estimate, Sales $12.02M Miss $13.48M Estimate
Champions Oncology reported quarterly losses of $0.16 per share. The company reported quarterly sales of $12.02 million. Champions oncology missed the analyst consensus estimate of $13.48 million by 10.84%. The company also reported a decrease in sales from the same period last year.
Benzinga · 03/12 20:41
Earnings Scheduled For March 12, 2024
Aurora Mobile is likely to report earnings for its fourth quarter. Manchester United is projected to report quarterly loss at $0.22 per share on revenue of $222.43 million. Kohl's is expected to report before the bell and after the bell. Other companies reporting before and after bell include Aurora Mobile, Enfusion and Hagerty.
Benzinga · 03/12 09:35
Earnings Outlook For Champions Oncology
Champions Oncology is set to give its latest quarterly earnings report on Tuesday, 2024-03-12. Analysts estimate the company will report an earnings per share of $-0.15. Last quarter the company beat EPS by $0.02. Shares of Champions oncology were trading at $5.7 as of March 08.
Benzinga · 03/11 18:00
Weekly Report: what happened at CSBR last week (0304-0308)?
Weekly Report · 03/11 11:46
Craig-Hallum Gives a Buy Rating to Champions Oncology (CSBR)
Craig-Hallum analyst Matt Hewitt assigned a Buy rating to the stock today. Champions Oncology has an analyst consensus of Moderate Buy. The company has a one-year high of $7.32 and a low of $3.95. The stock has a positive corporate insider sentiment.
TipRanks · 03/08 13:46
Weekly Report: what happened at CSBR last week (0226-0301)?
Weekly Report · 03/04 11:49
Weekly Report: what happened at CSBR last week (0219-0223)?
Weekly Report · 02/26 12:06
Weekly Report: what happened at CSBR last week (0212-0216)?
Weekly Report · 02/19 12:08
Weekly Report: what happened at CSBR last week (0205-0209)?
Weekly Report · 02/12 11:55
Weekly Report: what happened at CSBR last week (0129-0202)?
Weekly Report · 02/05 12:07
Weekly Report: what happened at CSBR last week (0122-0126)?
Weekly Report · 01/29 11:51
Analysts’ Top Healthcare Picks: Acurx Pharmaceuticals (ACXP), Champions Oncology (CSBR)
TipRanks · 01/22 18:21
Weekly Report: what happened at CSBR last week (0115-0119)?
Weekly Report · 01/22 11:56
Champions Oncolo: Statement of changes in beneficial ownership of securities
Press release · 01/16 18:04
More
Webull provides a variety of real-time CSBR stock news. You can receive the latest news about Champions Oncolo through multiple platforms. This information may help you make smarter investment decisions.
About CSBR
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.